CAR T cell therapies are often limited in effectiveness against solid tumors
The problem with current CAR T cell therapies is their limited effectiveness against solid tumors due to the expansion of non-specific T cell populations and the difficulty in isolating antigen-specific T cells. Conventional sorting methods exacerbate this issue by causing T cell receptor (TCR) hyperactivation and apoptosis.
The novel DNA-gated sorting (DGS) technology solves these problems by employing a DNA gate mechanism for the label-free, multiplexed isolation of antigen-specific CD8+ T cells. This technique enhances the scalability and therapeutic effectiveness of CAR T cells, leading to improved in vivo persistence and more effective treatment outcomes, particularly for solid tumors
A novel CAR T cell therapy improves therapeutic effectiveness
The technology introduces a novel approach to CAR T cell therapy through the development of DNA-gated sorting (DGS), a method for the label-free and multiplexed isolation of antigen (Ag)-specific CD8+ T cells. DGS employs a molecular 'DNA gate' mechanism that attaches a magnetic bead to peptide-major histocompatibility complex class I (pMHCI) molecules via DNA hybridization, enabling the targeted capture, release, and recovery of Ag-specific T cells through toehold-mediated strand displacement. This technique facilitates the generation of CAR T cells from these isolated Ag-specific T cells, leading to improved in vivo persistence and therapeutic effectiveness, particularly against solid tumors.
• Enhanced scalability through the use of synthetic DNA constructs, allowing for unprecedented multiplexing capabilities.
• Generation of label-free cell products
• Improved in vivo persistence and therapeutic effectiveness of CAR T cells
• Chimeric Antigen Receptor (CAR) T cell therapy for the treatment of solid tumors and other cancers.
• Enhanced cell therapy products with improved specificity, efficacy, and safety profiles.